Vaxart, Inc. (NASDAQ:VXRT – Free Report) – Cantor Fitzgerald raised their FY2023 earnings estimates for shares of Vaxart in a research report issued to clients and investors on Tuesday, November 14th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will earn ($0.56) per share for the year, up from their prior estimate of ($0.65). Cantor Fitzgerald has a “Overweight” rating and a $4.00 price objective on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.68) per share. Cantor Fitzgerald also issued estimates for Vaxart’s FY2024 earnings at ($0.42) EPS.
Vaxart Stock Performance
NASDAQ:VXRT opened at $0.80 on Friday. The company has a market capitalization of $121.48 million, a PE ratio of -1.25 and a beta of 0.71. The company has a 50 day simple moving average of $0.71 and a two-hundred day simple moving average of $0.83. Vaxart has a fifty-two week low of $0.56 and a fifty-two week high of $1.59.
Institutional Trading of Vaxart
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia.
- Five stocks we like better than Vaxart
- What Are Dividend Achievers? An Introduction
- 3 large caps with red hot RSIs with upside
- What is the Nikkei 225 index?
- Johnson Controls International: Nothing but upside for investors
- What is the Euro STOXX 50 Index?
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.